Mirvaso generic
Mirvaso is a topical treatment for facial erythema of rosacea, owned by Galderma Labs Lp. The drug, which is available in gel form, utilizes the active ingredient brimonidine tartrate. Mirvaso was first authorized for market use on August 23, 2013. It is protected by 12 drug patents, none of which have expired.
When will Mirvaso generic be available?
The generics of Mirvaso are expected to be released after June 13, 2031. This is following the expiration of the drug's last patent. It should be noted that the schedule of generic release can be influenced by various factors, including Para IV filings.
Mirvaso uses
Mirvaso, with its active ingredient brimonidine tartrate, provides efficient treatment for facial erythema of rosacea. This topical gel helps to reduce redness and inflammation associated with the skin condition.
Mirvaso patent expiration
Mirvaso is protected under 12 drug patents, the last of which is due to expire on June 13, 2031. Prior to the Mirvaso generic release, none of these patents have expired. Below are the details of the patent: